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ABSTRACT 
Background: Based on the efficacy of paromomycin ointment and recent ongoing clinical trials 
of combination of paromomycin and gentamicin, a new physical form of films of the paromomy-
cin and gentamicin was prepared and anti-Leishmania activities of the prepared films were as-
sessed in vitro and in vivo. 
Methods: Paromomycin 15% and gentamicin 0.5% was incorporated in a film using ethyl cellu-
lose and HPMC (Hydroxyl Propyl Methyl Cellulose). In order to assess the drug release and anti-
Leishmania activities of the preparation, a clone L. major parasite was established using a set of 
modified NNN medium without overlay liquid layer. Therapeutic effects of the films were evalu-
ated using Balb/c mice model. The mice were inoculated with 2×10
6 L. major promastigotes 
(MRHO/IR/75/ER) and then when the lesions developed the mice were randomly divided in 3 
groups, 10 mice per group, and treated with either perpetrated films or placebo for 28 days or left 
untreated.  
Results: Growth inhibition of cloned promastigotes showed that the films have enough releasing 
capacity and in vivo system, the films containing paromomycin and gentamicin was able to re-
duce the lesion size and induced complete cure in 80% of the mice but relapse was seen in 60% 
of the cured mice and overall 50% cure rate was seen during 20 weeks period of the study. 
Conclusion: It seems that the prepared films might be further used in human clinical trials.   
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Introduction 
  
urrently 350 million individuals in 
more than 88 countries are at risk of 
leishmaniasis. Recently due to 
increase in CL incidence rate and co-
infection of leishmaniasis with HIV, more 
attention is demanded to the neglected 
disease. Approximately 90% of all CL cases 
are reported from eight countries including 
Iran (1). However using antimony needs 
multiple injections, accompanies with side 
effects and the efficacy of antimony is very 
low especially in CL lesions induced by 
Leishmania tropica and resistant to anti-
mony is reported (2-4). Aminoglycoside 
antibiotics such as paromomycin showed to 
be effective against  Leishmania parasites 
and promising results generated in phase 3 
clinical trials (5-8). Topical therapy against 
CL if available is ideal since such topical 
therapy dramatically improves the patients' 
compliance. Currently topical formulation of 
paromomycin and gentamicin is in phase 3 
clinical trials (9) (Personal communication 
with Alan Magill and Max Grogl). 
In this study,  a physical form of film 
containing paromomycin 15% and gen-
tamicin 0.5% was prepared. The anti 
Leishmania activities of the films were as-
sessed in vitro and in vivo.   
 
Material and Methods 
 
Parasite 
Leishmania major strain (MRHO/IR/75/ER) 
used in this experiment is the same strain 
which was used for leishmanization and 
preparation of experimental Leishmania vac-
cine (10,11). 
 
Drug films 
The films were prepared at School of Phar-
macy, Isfahan University of Medical Sci-
ences using paromomycin 15% and gen-
tamicin 0.5% incorporated into ethyl cellu-
lose and Hydroxyl Propyl Methyl cellulose 
(HPMC). The films contain of backing layer, 
drug reservoir, rate controlling membrane, 
and adhesive layer. Direct compression and 
solvent casting methods are used to make 
films containing paromomycin and gen-
tamicin with permeation enhancer in poly-
meric matrices. Physical properties of the 
prepared films such as flexibility, stability, 
thickness, and apparent uniformity were 
checked. Releasing study was done by put-
ting the films on Bacillus subtilis culture and 
growth inhibition zone was assessed and 
compared with standard curve of discs con-
taining the same amount of paromomycin. 
 
In vitro experiments 
Leishmania promastigotes were harvested at 
stationary phase using a set of modified 
NNN medium without overlaid liquid layer. 
The plates were sealed with parafilm and 
incubated at 26 ± 1°C for 7-10 days, the sur-
face of the plates were checked for the 
growth of the promastigotes. Three types of 
culture plates were prepared triplicity as fol-
low; paromomycin and gentamicin incorpo-
rated into ethyl cellulose and HPMC film 
plates, placebo film plates and control media 
with no film. The same number of promas-
tigotes was cultured in the abovementioned 
three types of plates. After 4-5 days, the 
plates were checked for the growth of the 
promastigotes by direct microscopy and the 
number of motile and non-motile promas-
tigotes was determined. Viability of promas-
tigotes was also evaluated using trypan blue. 
 
In vivo experiments 
Female 6 -8 weeks old Balb/c mice were 
purchased from Pasteur Institute of Iran. The 
mice were inoculated at the ramp of the tail 
with 2×10
6 L. major promastigotes harvested 
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at stationary phase. The lesion was devel-
oped in the inoculation site after 2-3 weeks. 
Thirty mice with ulcerated lesion were se-
lected and randomly divided in to 3 groups 
(10 per group), the mice were treated with 
either films containing paromomycin 15% 
and gentamicin 0.5% or placebo, and one 
group was left untreated. The films were 
changed every 4 days for 28 days; each 
mouse received 7 films. At the time of 
changing the film, the size of ulcer in each 
mouse  was measured using vernier scale. 
The mice were followed up for up to 4 
months. 
ANOVA test was used to analyze the data 
and p<0.05% was considered significant.  
 
Results 
 
In vitro experiments 
No growth of Leishmania was seen in a 30 
mm radius of the drug films. On the other 
hand, growth of  Leishmania promastigotes 
was seen in placebo and control plates, wet 
mount smears proved the presence of alive, 
and motile promastigotes in placebo and 
control plates. Among 1,000 promastigotes 
was counted, 971±3.6 (97%), in placebo 
plates and 980±5 (98%) in control plates 
showed to be alive, but in the experimental 
plates 101±6 (10%) promastigotes showed to 
be alive (Table 1). 
 
In vivo experiments  
Lesions appeared at 2-3 weeks after inocula-
tion at the base of the tails. The lesions size 
in group of mice which received the films 
was significantly ( P <0.05%) smaller than 
the control groups (Fig. 1). In control groups 
receiving either placebo or no treatment the 
lesion size continue to progress throughout 
the 20 weeks duration of the study (Fig. 1). 
Mean diameter of lesion size in the experi-
mental group was 0.4±0.04 mm, in placebo 
group  was 5.04±0.20 mm and in none 
treated group was 6.42±0.44 mm. At the end 
of the treatment course 80% of the animals 
were cured in the experimental  group and 
the mean diameter of the lesions showed to 
be significantly ( P <0.05) decreased in the 
20% of the mice with the lesion (1 mm). 
  
 
Table 1: In vitro effect of drug and placebo film on L. major growth 
Total 
count 
Dead parasite 
X±SD         % 
Live parasite 
X±SD            % 
Plate 
 
1000  90  899±6  10  101±6  Plate with drug film 
1000  3  29±6  97  971±3.6  Plate with placebo 
1000  2  20±5  98  980±5  Plate without drug film 
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Fig. 1: Ulcer size in Balb/c mice infected with L. major, animals were treated with drug films or 
placebo or left untreated for 28 days (4 weeks) 
 
 
Discussion 
 
Although leishmaniasis is a major health 
problem in some of the endemic areas(12)  , 
no vaccine is available against any form of 
leishmaniasis (10-13). Available chemother-
apy against CL is limited and daily injec-
tions is difficult to tolerate by the patients 
and justifies search for more practical 
formulation of chemotherapy and topical 
therapy is highly acceptable if available (14-
16).Therapeutic activities of paromomycin 
against CL is tested in several clinical trials, 
although the results are not consistent but the 
overall showed that at least paromomycin is 
effective against some  Leishmania strains 
(5,7,15,17,18). Combination of paromomy-
cin and gentamicin was showed to cure L. 
major and  L. mexicana in infected Balb/c 
mice (19). 
The same formulation called WR279396 
was checked in phase 2 trials and showed to 
be safe with acceptable cure rate and cur-
rently is in phase 3 clinical trial in Tunesia 
and Columbian male army (9, 20) (Personal 
communication with Alan Magill and Max 
Grogl). In the current study, a new form of 
film containing of paromomycin and gen-
tamicin was prepared and tested in vitro 
against L. major growth and in vivo against 
L. major infection in Balb/c mice. 
Paromomycin is effective against  Leishma-
nia infection and gentamicin is a wide spec-
trum antibiotic that has synergic effects in 
combination of paromomycin (17-19). In 
this study, drug films were shown to be 
effective against in vitro promastigote 
growth with inhibition rate of 98% within 5 
days. The in vivo results indicated that the 
new physical form of combination of 
paromomycin and gentamicin was able to 
significantly (P<0.05) reduce the lesion size 
in Balb/c mice. Drug films were able to in-
duce lesion cure in 80% of the mice at 28 
days after the treatment initiation. However 
relapses characterized by the reappearance Iranian J Parasitol: Vol. 6, No.3, 2011, pp.60-65 
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of the lesion, was observed at week 9 to 11 
in cured mice which declined the cure rate 
from 80% to 50% in the experimental group, 
considering the fact that Balb/c mice are 
highly susceptible to L. major infection and 
this strain of mice is unable to control the 
infection even with therapy (6).   
In conclusion, the results suggested that topi-
cal films might be useful for the treatment of 
cutaneous leishmaniasis. The advantages of 
using film form of the drug as follows: 
Continuous contact of the drug with the le-
sions, which promote cure rate, also gradual 
release of the drug provides parasiticidal ef-
fects of the drug continuously. Low efficacy 
of different forms of paromomycin like lo-
tion or ointment in some studies might be 
due to a short contact period of the drug with 
the lesions or removal of the drug by the pa-
tients’ daily activities, in case of using films 
containing the drug guarantees continues 
contact of the drug with the lesion.  Finally, 
Human trials are needed to prove the possi-
ble efficacy of the preparation.  
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